Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

11.62 +0.02 (+0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
5 Value Stocks In The Healthcare Sector
Via Benzinga
The Terrible Ten
Most of the aforementioned group of quotable experts expect some mean reversion for the top stocks in the S&P 500 and counsel avoiding market cap weighting in favor of equal weighting. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The Terrible Ten
Many strategists recommend equal weighting over cap-weighting, claiming that over time, equal weighting always outperforms. 
Via Talk Markets
(VTRS) - Analyzing Viatris's Short Interest
Via Benzinga
These 9 Stocks Are Running To Start 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Recap: Viatris Q3 Earnings
Via Benzinga
2 Top Value Stocks to Buy in October
These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects. 
Via The Motley Fool
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS) 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?
Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist... 
Via Benzinga
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC. 
Via Benzinga
Topics ETFs
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
Wednesday, a court ruling that found Viatris Inc's (NASDAQ: 
Via Benzinga
3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric
Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value. 
Via Talk Markets
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. 
Via InvestorPlace
7 Low P/E Stocks Poised to Rebound
Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves. 
Via InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
3 Large-Cap Stocks to Buy Trading Below Book Value
There aren’t too many large-cap stocks in the S&P 500 trading below book value. But here are three possibilities. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Viatris now faces a narrower path to commercializing a generic copy of Ozempic. 
Via The Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
There's a chance shareholders won't notice any difference. 
Via The Motley Fool
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
These stocks may not be for everyone, but income-seekers might find what they're looking for in them. 
Via The Motley Fool
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
The company is retaining the rights to specific over-the-counter drugs in some markets. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.